InnoCare (诺诚健华) IPO Trading: At the Mercy of Retail Flipping
InnoCare, a China-based biotech company founded by a famous scientist, raised USD 270 million at HKD 8.95 per share. In this insight, we will cover...
565 Views
Akesobio (康方生物) Pre-IPO: Thoughts on Valuation
Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...
711 Views
InnoCare Pharma IPO Initiation: Promising Prognosis
InnoCare Pharma Ltd (1576300D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
500 Views
Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising
Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...
709 Views
2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
648 Views